Under the draft guidance, the FDA could fine researchers who submit false or incomplete data to ClinicalTrials.gov, a clinical trials database maintained by the U.S. National Library of Medicine. The guidance covers researchers submitting data to the FDA regarding drug, biological and device products who violate requirements mandated under the Federal Food, Drug, and Cosmetic Act.
The draft guidance, developed by three centers at the FDA, follows periodic reports of hospitals failing to submit required data to the database, according to Politico‘s Morning eHealth newsletter.
To view the FDA’s draft guidance, click here. The FDA is accepting comments on the draft guidance through Nov. 20.
More articles on supply chain:
Apple Watch: FDA-cleared for electrocardiogram screening
FDA scolds pharmaceutical lab for operating microbrewery in drug testing space
Amazon, Merck, Accenture to launch data-driven drug development platform
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.